BioCentury
ARTICLE | Clinical News

NOMAC/E2: Completed Phase III enrollment

May 28, 2007 7:00 AM UTC

AKZ's Organon BioSciences N.V. unit completed enrollment of 2,080 patients in the open-label, active-controlled, international Phase III 292001 trial to compare oral NOMAC/E2 vs. separate 2.5 mg of N...